Ionis (IONS) Hold rating reiterated at Stifel after Innovation Day presentation
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating and $67.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented, "IONS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
